Profusa, Inc. (PFSA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US74319X2071

Price
0.41 USD
Market cap
1,359.13 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Profusa, Inc. financials

Fiscal year2025
Operating income-27.71 m USD
EBIT-33.30 m USD
Net income-35.82 m USD
Diluted EPS – continuing operations-107.01 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Profusa, Inc.

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.